Androgen deprivation induces rapid involution and recovery of human prostate vasculature

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 2, 2011, Pages

  Godoy, Alejandro ^a   Montecinos, Viviana P ^a   Gray, Danny R ^b   Sotomayor, Paula ^a   Yau, Jeffrey M ^c   Vethanayagam, R Robert ^a   Singh, Swaroop ^a   Mohler, James L ^a,d   Smith, Gary J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Human prostate vasculature; Primary xenograft; Prostate; Vascular endothelial growth factor A

Indexed keywords

ANDROGEN; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TESTOSTERONE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANDROGEN DEPRIVATION; ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; TESTOSTERONE BLOOD LEVEL; VASCULARIZATION; XENOGRAFT;

ANDROGENS; ANGIOGENIC PROTEINS; ANIMALS; CAPILLARIES; CELLS, CULTURED; FIBRINOGEN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROSTATE; PROSTATIC NEOPLASMS; REGIONAL BLOOD FLOW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TESTOSTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79251577346     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00210.2010     Document Type: Article

References (68)

1. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82: 3493-3497, 1997. (Pubitemid 27419110)
2. Alessandri G, Chirivi RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM, Zanetta G, Landoni F, Graziotti PP, Turano A, Caruso A, Zardi L, Giavazzi R, Bani MR. Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastasis 17: 655-662, 1999.
3. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999.
4. Blauer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol 97: 264-268, 1991.
5. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 10: 415-420, 2000.
6. Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61: 2-7, 2003.
7. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253: 89-101, 2003.
8. Cruz D, Valenti C, Dias A, Seixas M, Schmitt F. Microvessel density counting in breast cancer. Slides vs digital images. Anal Quant Cytol Histol 23: 15-20, 2001.
9. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485, 2002.
10. Delia D, Lampugnani MG, Resnati M, Dejana E, Aiello A, Fontanella E, Soligo D, Pierotti MA, Greaves MF. CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood 81: 1001-1008, 1993.
11. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280: C1367-C1374, 2001.
12. Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic hyperplasia. Am Fam Physician 66: 77-84, 2002.
13. English HF, Drago JR, Santen RJ. Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate 7: 41-51, 1985.
14. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139: 441-442, 1998.
15. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139: 451-456, 1998.
16. Gabril M, Xuan J, Moussa M, Dinney CP, Chin JL, Izawa JI. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology 64: 1233-1237, 2004.
17. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 3: 285-291, 2002.
18. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11: 35-40, 2001.
19. Godoy A, Ormazabal V, Moraga-Cid G, Zuniga FA, Sotomayor P, Barra V, Vasquez O, Montecinos V, Mardones L, Guzman C, Villagran M, Aguayo LG, Onate SA, Reyes AM, Carcamo JG, Rivas CI, Vera JC. Mechanistic insights and functional determinants of the transport cycle of the ascorbic acid transporter SVCT2. Activation by sodium and absolute dependence on bivalent cations. J Biol Chem 282: 615-624, 2007.
20. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 149: 2959-2969, 2008.
21. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 49: 319-324, 1995.
22. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK Jr, Smith GJ. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 64: 1712-1721, 2004.
23. Gustavsson H, Welen K, Damber JE. Transition of an androgendependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005.
24. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, Burchardt M, Olsson CA, Buttyan R. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol 162: 1527-1531, 1999.
25. Hollander MWD. Nonparametric Statistical Methods. New York, NY: Wiley, 1999.
26. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 52: 213-235, 2002.
27. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95: 10820-10825, 1998.
28. Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 96: 503-507, 2005.
29. Kanimoto Y, Okada K. Antiandrogen therapy of benign prostatic hyperplasia- review of the agents evaluation of the clinical results. Hinyokika Kiyo 37: 1423-1428, 1991.
30. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 19: 631-636, 2005.
31. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513, 1999.
32. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 8: 487-495, 2001.
33. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 73: 1274-1278, 2009.
34. Lacorre DA, Baekkevold ES, Garrido I, Brandtzaeg P, Haraldsen G, Amalric F, Girard JP. Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment. Blood 103: 4164-4172, 2004.
35. Laine M, Blauer M, Ylikomi T, Tuohimaa P, Aitasalo K, Happonen RP, Tenovuo J. Immunohistochemical demonstration of androgen receptors in human salivary glands. Arch Oral Biol 38: 299-302, 1993.
36. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 25: 309-314, 1997.
37. Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 30: 23-66, 2010.
38. Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA, Liao S. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 100: 663-666, 1993. (Pubitemid 23128363)
39. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35: 437-452, 2001.
40. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol 137: 1000-1002, 1987.
41. Madan RA, Dahut WL. Angiogenesis inhibition in the treatment of prostate cancer. Anticancer Agents Med Chem 9: 1070-1078, 2009.
42. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621, 2006.
43. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, Wu JH. Localization of androgen receptor expression in human bone marrow. J Pathol 193: 361-366, 2001.
44. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61: 332-353, 2004.
45. Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL. Central quadrant procurement of radical prostatectomy specimens. Prostate 69: 770-773, 2009.
46. Oesterling JE. Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology 43: 7-16, 1994.
47. Oesterling JE, el Etreby MF, Gormley GJ, Imperato-McGinley JL, Roehrborn CG, Schroder FH, Tunn UW. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. Prog Clin Biol Res 386: 231-250, 1994.
48. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947-C970, 2002.
49. Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ. Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 159: 855-860, 2001.
50. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 129: 3187-3199, 1991.
51. Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9: 295-301, 2004.
52. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142-148, 1995.
53. Schultheiss D, Badalyan R, Pilatz A, Gabouev AI, Schlote N, Wefer J, von Wasielewski R, Mertsching H, Sohn M, Stief CG, Jonas U. Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 21: 320-324, 2003.
54. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
55. Shabsigh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, Heitjan D, Kiss A, Buttyan R. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 140: 1920-1926, 1999.
56. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 36: 201-206, 1998.
57. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 81: 437-444, 2001.
58. Shabsigh A, Lee B, Buttyan R. Unique morphological aspects of the rat ventral prostate gland revealed by vascular corrosion casting. Prostate 39: 240-245, 1999.
59. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. J Am Med Assoc 294: 238-244, 2005.
60. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 89: 5245-5255, 2004.
61. Stachon A, Schluter T, Koller M, Weisser H, Krieg M. Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. Prostate 48: 156-164, 2001.
62. Tempany CM, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 22: 39-42, 1993.
63. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 5: 40-46, 2000.
64. Van Steenbrigge GJ. The nude mouse in oncology research. In: Hormones, edited by Boven E and Winograd B. Boston, MA: CRC, 1991, p. 216-226.
65. Vega-Diaz B, Herron GS, Michel S. An autocrine loop mediates expression of vascular endothelial growth factor in human dermal microvascular endothelial cells. J Invest Dermatol 116: 525-530, 2001. (Pubitemid 32299840)
66. Volavsek M, Masera A, Ovcak Z. Incidental prostatic carcinoma. A predictive role of neoangiogenesis and comparison with other prognostic factors. Pathol Oncol Res 6: 191-196, 2000.
67. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 95: 355-360, 1982.
68. Wilson MJ, Sinha AA. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells. Anat Rec 249: 63-73, 1997.